TRACKER Takes the Global Stage

---

Lung cancer remains a leading cause of cancer-related deaths worldwide, but the TRACKER Biobank is forging a path toward change through innovation and collaboration. At the prestigious World Congress for Bronchology and Interventional Pulmonology (WCBIP/WCBE) in Bali, TRACKER achieved a major milestone with its first international presentation, marking a significant step in its mission to transform lung cancer research.

---

Dr. Sarah Yeo, a clinician and TRACKER PhD student, presented key findings from the first 70 patients enrolled in the biobank. Her presentation highlighted TRACKER’s ability to accurately represent the Australian patient population while sharing plans to tackle the critical challenge of immunotherapy resistance.

"Sharing our findings at an international forum like WCBIP/WCBE is an incredible milestone for our team. It reflects not only the progress we’ve made but also our commitment to improving outcomes for lung cancer patients worldwide.” 

 _____________

Dr. Sarah Yeo, TRACKER PhD Student

Transforming Research Through Collaboration

WCBIP/WCBE is renowned for bringing together leading global experts in bronchology and interventional pulmonology. TRACKER’s participation offered a valuable platform to share its cutting-edge research, build international collaborations, and contribute to collective efforts in addressing one of the world’s deadliest cancers.

During her presentation, Dr. Yeo highlighted the transformative potential of longitudinal biobanking. TRACKER’s innovative approach — collecting blood, tissue, and lung fluid samples over time — addresses a critical gap in lung cancer research. This method is instrumental in uncovering why certain patients fail to respond to existing treatments, paving the way for more targeted and effective therapies.

Driving Innovation

As Australia’s first biobank of its kind, TRACKER is at the forefront of advancing lung cancer research. Its mission is to facilitate quality research. This includes deepening our understanding of treatment resistance and delivering therapies that are not only more effective but also tolerable and accessible, ultimately improving the quality of life for patients worldwide.

“Our vision is a future where every lung cancer patient has access to innovative, personalised treatments that offer the best chance for survival,” Dr. Yeo added.

TRACKER’s international debut marks the start of an exciting chapter in its journey. With ongoing research and a steadfast commitment to global collaboration, TRACKER is poised to make a lasting impact on lung cancer outcomes.